ANI Pharmaceuticals Inc (Nasdaq: ANIP), an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals, yesterday announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg and 32mg/25mg, an authorized generic of Atacand HCT.
The product is indicated for the treatment of hypertension.
Arthur S Przybyl, ANI's president and CEO, said, 'We are pleased to announce the launch of the authorized generic of our brand product Atacand HCT. This launch represents ANI's sixth generic new product introduction in 2018.'
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream